MedTrace Logo

Deprescribing Intervention Among Nursing Home Residents With Major Neurocognitive Disorders

NCT05155748 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-12-14

No results posted yet for this study

Summary

Canadians with neurocognitive disorders often are admitted to nursing homes when their disease reaches an advanced stage. At the end of their life, they may encounter adverse symptoms related to medications they no longer need, while they should receive comfort care. This study proposes an intervention to reduce the use of inappropriate medications among residents of nursing homes with major neurocognitive disorders. For that purpose, nursing homes' nursing staff, physicians and pharmacists will receive education and tools for the review, adjustment or discontinuation of the medications that have become inappropriate for the residents. The residents' families will receive information regarding the complexity of drug treatment for elderly patients with major neurocognitive disorders and they will be kept informed about the proposed changes to their relative's medication. The intervention is expected to reduce the medication load while improving or maintaining the residents' well-being.

Conditions

Interventions

OTHER

Continuous education and knowledge exchange

The intervention is educational and directed at the complete nursing home care team.

Sponsors & Collaborators

  • Alzheimer Society of Canada

    collaborator OTHER

  • Dre Edeltraut Kröger

    lead OTHER

Principal Investigators

  • Edeltraut Kröger, Ph.D. · CHU de Québec

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-06
Primary Completion
2019-01-31
Completion
2019-02-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05155748 on ClinicalTrials.gov